A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer

Within PrefHer (NCT01401166), patients and healthcare professionals (HCPs) preferred subcutaneous (SC) over intravenous (IV) trastuzumab. We undertook a prospective, observational time and motion study to quantify patients’ time in infusion chairs and active HCP time in PrefHer. Patients with HER2‐p...

Descripción completa

Detalles Bibliográficos
Autores principales: De Cock, Erwin, Pivot, Xavier, Hauser, Nik, Verma, Sunil, Kritikou, Persefoni, Millar, Douglas, Knoop, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799946/
https://www.ncbi.nlm.nih.gov/pubmed/26806010
http://dx.doi.org/10.1002/cam4.573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799946/
https://www.ncbi.nlm.nih.gov/pubmed/26806010
http://dx.doi.org/10.1002/cam4.573

Ejemplares similares